Repligen (NASDAQ:RGEN – Get Free Report) was upgraded by equities research analysts at Wolfe Research to a “strong-buy” rating in a report released on Monday,Zacks.com reports.
Several other research firms have also commented on RGEN. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 7th. UBS Group cut their price target on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Barclays boosted their price objective on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Jefferies Financial Group reaffirmed a “hold” rating and set a $142.00 target price on shares of Repligen in a research note on Tuesday, May 5th. Finally, Royal Bank Of Canada began coverage on Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $164.64.
View Our Latest Report on Repligen
Repligen Stock Performance
Repligen (NASDAQ:RGEN – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $194.26 million during the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities research analysts predict that Repligen will post 1.99 EPS for the current year.
Institutional Trading of Repligen
Large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its position in shares of Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after acquiring an additional 1,091,683 shares during the last quarter. United Capital Financial Advisors LLC acquired a new stake in shares of Repligen during the third quarter worth approximately $368,387,000. Opti Capital Management LP purchased a new position in Repligen during the fourth quarter valued at approximately $2,399,209,000. Maverick Capital Ltd. acquired a new position in Repligen in the 1st quarter valued at approximately $178,946,000. Finally, Holocene Advisors LP increased its stake in Repligen by 47.0% in the 3rd quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock valued at $184,077,000 after buying an additional 440,290 shares during the period. 97.64% of the stock is currently owned by institutional investors.
About Repligen
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Recommended Stories
- Five stocks we like better than Repligen
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
